Gonadorelin (synthetic GnRH, Factrel, Lutrepulse)

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH) — the 10-amino-acid hypothalamic peptide that orchestrates the entire male and female reproductive endocrine axis. It is identical in sequence to the endogenous GnRH your hypothalamus produces in pulsatile bursts throughout the day. Brand names include Factrel (diagnostic use) and Lutrepulse (pulsatile infusion pump for infertility).

The community-driven use case that dominates 2024-2026 discussion is as an HCG alternative for men on testosterone replacement therapy (TRT). When a man takes exogenous testosterone, the hypothalamic-pituitary-gonadal (HPG) axis shuts down — the brain detects sufficient circulating androgens and stops producing GnRH, which in turn stops LH and FSH release, which stops endogenous testosterone production and spermatogenesis in the testes. The clinical consequence: testicular atrophy and infertility while on TRT. HCG traditionally addressed this by directly stimulating testicular Leydig cells (HCG mimics LH at the receptor); Gonadorelin addresses it by replacing the upstream hypothalamic signal that the suppressed natural pulsatile rhythm has lost.

Why Gonadorelin replaced HCG for many TRT patients: HCG access tightened substantially in 2023-2024. The FDA's 503B compounding restrictions reclassified HCG production rules, supply chains were disrupted, prices increased, and many TRT clinics began routinely prescribing Gonadorelin as the standard testicular-function adjuvant for new TRT starts. By 2025-2026, Gonadorelin is the more commonly prescribed of the two in modern TRT practice.

Gonadorelin was first synthesized in 1971 by Andrew Schally's group at Tulane University, characterizing the structure of endogenous gonadotropin-releasing hormone (GnRH). Schally shared the 1977 Nobel Prize in Physiology or Medicine for the work on hypothalamic hormones. As a synthetic version of the body's own GnRH, Gonadorelin has identical structure to the endogenous hormone — it's not a modified analog like leuprolide (Lupron) or triptorelin, which are GnRH agonists engineered for sustained receptor activation rather than the brief pulsatile signal that natural GnRH provides.

Gonadorelin activates the hypothalamic-pituitary-gonadal (HPG) axis at its upstream entry point. The cascade:

1. Gonadorelin binds GnRH receptors on anterior pituitary gonadotrope cells.
2. Pituitary releases LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in response. The ratio depends on dose pattern and physiologic state.
3. LH acts on testicular Leydig cells → endogenous testosterone production.
4. FSH acts on testicular Sertoli cells → spermatogenesis support.
5. Net effect: Endogenous testosterone production and fertility preservation while on exogenous TRT.

The pulsatile-vs-continuous distinction is fundamental. Natural GnRH is released in pulses every 60-120 minutes. The pituitary GnRH receptor responds to this pulsatile pattern by releasing LH/FSH. Sustained or continuous GnRH receptor activation produces the opposite effect — receptor downregulation and HPG axis suppression. This is why leuprolide (Lupron) and other GnRH "agonists" engineered for sustained activation produce medical castration, while Gonadorelin's short half-life and intermittent dosing preserves the physiologic signaling pattern. Dosing protocol matters substantially — large single doses or continuous infusion fail to produce the desired effect.

Mechanistic comparison to HCG: HCG bypasses the pituitary and acts directly on Leydig cells. The two compounds therefore preserve different aspects of testicular function. Gonadorelin maintains both LH and FSH signaling, supporting both testosterone and spermatogenesis. HCG provides LH-like signaling but doesn't restore FSH — so spermatogenesis support is less complete with HCG alone (often requiring additional FSH or hMG in fertility-restoration protocols). For pure testicular volume preservation, both work; for fertility preservation, Gonadorelin has the theoretical advantage of FSH coverage.

Gonadorelin has a very short plasma half-life — 2 to 10 minutes — reflecting its biology as a pulsatile hypothalamic signal rather than a circulating hormone. This is mechanistically critical: the pituitary GnRH receptor responds to pulsatile stimulation by releasing LH and FSH, but downregulates in response to continuous receptor activation (the mechanism by which the long-acting GnRH agonists like leuprolide produce medical castration). Gonadorelin's short half-life and pulsatile dosing pattern preserves the physiologic stimulation pattern; continuous infusion or large single doses paradoxically suppress the axis rather than activating it.

The peer-reviewed literature on Gonadorelin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

The defining feature of effective Gonadorelin administration is the pulsatile pattern. Continuous or high-dose single-bolus administration paradoxically suppresses the HPG axis rather than activating it. Standard community-practice protocols for TRT adjuvant use involve small subcutaneous doses 2-3 times weekly or daily, mimicking the natural pulsatile rhythm. Specific dosing varies by prescribing physician; some compounding pharmacies provide standardized injection protocols with their formulations.

For the FDA-approved diagnostic and pulsatile-pump indications, formal dosing protocols are well-established in product labeling. For the off-label TRT-adjuvant use, dosing comes from clinical practice patterns rather than formal trials.

Gonadorelin is the modern replacement for HCG in TRT practice — synthetic GnRH that maintains testicular function and fertility through upstream HPG-axis stimulation rather than direct testicular receptor activation. The 2023-2024 tightening of HCG access drove a major shift to Gonadorelin as the standard adjuvant for new TRT prescriptions. The mechanism is well-established, the clinical experience base is substantial, the side-effect profile is favorable, and access through compounding pharmacies is reasonable in current markets.

For users on or considering TRT, Gonadorelin represents the current best-practice approach to testicular function and fertility preservation in 2026. The pulsatile dosing pattern matters substantially — protocol adherence is mechanistically critical, not just a recommendation. For users specifically targeting full HPG-axis activation, the emerging Kisspeptin compound activates the system one step further upstream and is increasingly combined with Gonadorelin in the HPG Axis Testosterone Support stack.

For TRT-curious readers, the community discussion lives primarily on ExcelMale, r/Testosterone, and the broader TRT-medical-practice forums. Clinical management by a qualified TRT-experienced prescriber is the appropriate framework — TRT itself is a substantial medical intervention and the adjuvant compounds layered on top warrant prescribing-physician oversight rather than self-experimentation.